We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+7.56%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$115M
AUM Growth
-$80.1M
Cap. Flow
-$107M
Cap. Flow %
-93.27%
Top 10 Hldgs %
68.73%
Holding
65
New
15
Increased
2
Reduced
17
Closed
31

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$5.83M
2
IQV icon
IQVIA
IQV
+$3.85M
3
BSX icon
Boston Scientific
BSX
+$3.19M
4
CAH icon
Cardinal Health
CAH
+$2.68M
5
MDT icon
Medtronic
MDT
+$2.34M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20M
2
BDX icon
Becton Dickinson
BDX
+$16.1M
3
ELV icon
Elevance Health
ELV
+$14.6M
4
SBRA icon
Sabra Healthcare REIT
SBRA
+$13.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.18M

Sector Composition

Rank Sector Weight
1 Healthcare 66.02%
2 Real Estate 1.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$27.1M 23.7%
+6,100
New +$2.56M
BMRN icon
2
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
$8.11M 7.08%
+93,600
New +$8.81M
LH icon
3
Labcorp
LH
$25B
$7.86M 6.86%
37,910
-14,749
-28% -$2.86M
CI icon
4
Cigna
CI
$73.7B
$7.24M 6.32%
25,816
-1,983
-7% -$516K
MRK icon
5
Merck
MRK
$322B
$5.69M 4.97%
49,332
-241
-0.5% -$27.4K
A icon
6
Agilent Technologies
A
$39.1B
$5.5M 4.8%
+45,762
New +$5.83M
THC icon
7
Tenet Healthcare
THC
$20.5B
$4.72M 4.12%
58,036
-1,867
-3% -$133K
AZN icon
8
AstraZeneca
AZN
$263B
$4.35M 3.8%
30,404
-18,225
-37% -$2.68M
IQV icon
9
IQVIA
IQV
$38.7B
$4.31M 3.76%
+19,169
New +$3.85M
BMRN icon
10
BioMarin Pharmaceuticals
BMRN
$11.6B
$3.78M 3.3%
43,602
-212,014
-83% -$20M
BDX icon
11
Becton Dickinson
BDX
$45.6B
$3.53M 3.08%
13,360
-63,490
-83% -$16.1M
BSX icon
12
Boston Scientific
BSX
$69.5B
$3.3M 2.88%
+60,991
New +$3.19M
CAH icon
13
Cardinal Health
CAH
$53.9B
$3M 2.62%
+31,696
New +$2.68M
QGEN icon
14
Qiagen
QGEN
$8.54B
$2.82M 2.47%
59,137
-109,570
-65% -$5.28M
ELV icon
15
Elevance Health
ELV
$81.5B
$2.5M 2.19%
5,636
-31,690
-85% -$14.6M
MDT icon
16
Medtronic
MDT
$109B
$2.39M 2.09%
+27,181
New +$2.34M
EHC icon
17
Encompass Health
EHC
$11B
$2.21M 1.93%
32,710
+6,239
+24% +$391K
VTR icon
18
Ventas
VTR
$48B
$1.97M 1.72%
+41,575
New +$1.88M
OCUL icon
19
Ocular Therapeutix
OCUL
$1.79B
$1.9M 1.66%
368,438
-144,306
-28% -$858K
INSM icon
20
Insmed
INSM
$21.4B
$1.68M 1.46%
79,471
-150,535
-65% -$2.86M
TEVA icon
21
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$1.32M 1.15%
+175,000
New +$1.42M
ZTS icon
22
Zoetis
ZTS
$32.4B
$1.32M 1.15%
7,643
-771
-9% -$133K
BRKR icon
23
Bruker
BRKR
$9.57B
$1.13M 0.98%
+15,246
New +$1.16M
ARGX icon
24
argenx
ARGX
$53.4B
$1,000K 0.87%
2,565
-3,572
-58% -$1.4M
BLUE
25
DELISTED
bluebird bio
BLUE
$926K 0.81%
14,072
-12,181
-46% -$891K
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Endurant Capital Management held 65 positions worth $115M, down 41% from $195M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Endurant Capital Management withdrew a net $107M in Q2 2023, closing 31 positions and reducing 17 holdings. Its most notable exit was Sabra Healthcare REIT, an estimated $13.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 92% a quarter earlier, followed by Real Estate.

Against the trend, Endurant Capital Management opened a new position in Agilent Technologies worth $5.5M.

  • Endurant Capital Management's largest Q2 2023 buy was Agilent Technologies: 45,762 shares worth $5.5M.
  • Endurant Capital Management added most to Encompass Health in Q2 2023, an estimated $391K increase.
  • Endurant Capital Management's biggest Q2 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $20M.
  • Endurant Capital Management fully exited Sabra Healthcare REIT in Q2 2023, selling an estimated $13.4M.
  • Endurant Capital Management's ten largest holdings make up 69% of its $115M portfolio in Q2 2023.
  • Endurant Capital Management opened 15 new positions and closed 31 in Q2 2023.
  • Endurant Capital Management's portfolio value fell 41% quarter-over-quarter to $115M.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.